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Summary.-The urinary excretion during 24 h of aminoglutethimide (AG) its major
metabolite (N-acetylAG) and two minor metabolites (N-formylAG and nitroG) were
measured in 10 volunteers given AG who had been typed for acetylator phenotype
using sulphadimidine. The slow acetylators of sulphadimidine excreted more AG
(mean 28% of the administered dose) than did the fast acetylators (12%), but the
latter excreted more of the dose as N-acetylAG (8.8%) than did the former (3.9O%).
NitroG and N-formylAG were minor urinary metabolites of AG in humans. The
former was more abundant in the urine of slow acetylators (0-10% of the dose) than
in that of fast acetylators (0.047%o), whereas the respective proportions of doses
excreted as the N-formyl derivative (0-475 and0-465%o) were not significantly different
for the two acetylator phenotypes. These results show that AG is among those drugs
that are polymorphically acetylated in humans.
AMINOGLUTETHIMIDE (Elipten, CIBA,
Horsham: AG) is an effective agent in the
treatment ofmammary carcinoma in post-
menopausal women (Smith et al., 1978). It
acts by inhibiting adrenal steroidogenesis,
thereby effecting a "medical adrenal-
ectomy". N-AcetylAG (Douglas &
Nicholls, 1972) is the major urinary
metabolite in humans, accounting for
4-25% of the administered dose. Com-
pared with AG, the N-acetyl derivative is
a poor inhibitor of steroidogenesis, as
measured by ability to reduce corticoster-
oid output in bovine adrenal cells in
culture. Thus, 10 jg/ml of the parent
compound reduced glucocorticoid produc-
tion to 833% of the resting levels, whereas
this concentration of the N-acetylated
compound reduced it only to 58% of
resting levels (Coombes et al., 1980). From
the therapeutic viewpoint, therefore, N-
acetylation represents adverse metabolism
of AG, and it becomes important to
consider the extent to which N-acetylation
prejudices thetherapeutic effectofthedrug.
N-Acetylation of many drugs is genetic-
ally controlled in humans and other
species, a bimodal distribution into rapid
and slow acetylators being observed
(Price-Evans & White, 1964). Acetylation
is not invariably polymorphic. Thus,
whereas isoniazid, sulphamethazine and
diaminodiphenylsulphone are polymor-
phically acetylated in humans, p-amino-
benzoic acid and sulphanilamide are not
(Testa & Jenner, 1976). Where the drug
and its N-acetyl derivative differ in
therapeutic efficacy or in their side effects,
response may depend upon acetylator
phenotype. Thus both procainamide
(Woosley et al., 1978) and hydralazine
(Perry et al., 1970) induced the adverse
side-effect of lupus erythematosus, pre-
ponderantly in those subjects who were
slow acetylators, implicating the parent
drug as the cause of this reaction.
AG also frequently elicits side effects in
patients, in particular skin rash and
lethargy (Smith et al., 1978). The sedative
effect is dose-limiting and is not dependentPOLYMORPHIC ACETYLATION OF AMINOGLUTETHIMIDE
on the presence ofthe amino function since
the parent drug, glutethimide (Doriden,
CIBA), which has little inhibitory effect on
steroidogenesis, is a powerful hypnotic
(Hoffman & Tagmann, 1954). Should N-
acetylAG also possess hypnotic activity,
any factor which depletes this metabolite
may improve the therapeutic effect with-
out simultaneously augmenting the hyp-
notic activity. Hence it is relevant to
consider whether AG is polymorphically
acetylated, as the first step to assessing the
significance of N-acetylation in the thera-
peutic and toxic effects of this drug in
humans.
N-FormylAG and nitroG are additional,
though minor urinary metabolites ofAG in
humans (Baker et al., 1981). The present
study also considers the quantitative
relationship between their formation and
that of the N-acetyl derivative.
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METHODS
Drugadministrationandsample collection.-
Ten healthy laboratory personnel (age range
22-39 mean 28) were evaluated for acetylator
phenotype, using sulphadimidine, by the
method of Price-Evans (1969). Each subse-
quently took AG (250mg tablet, orally) after
fasting overnight. A 24h urine sample was
collected, the volume recorded and a sample
(50 ml) was stored at -30TC for analysis.
Quantification of urinary metabolites.-
Urine (1 ml) was extracted with dichloro-
methane (10 ml). The extract was concentra-
ted and the residue was dissolved in ethyl
acetate (200 tul). Aliquots (80 ,u) were used
for HPLC analysis (Waters Model ALC/GPC
204 Liquid Chromatograph) on a Spherisorb
5,t C6 column operating at 23-5°C by elu-
tion with acetonitrile-water-perchloric acid
(22:78:0.05) and detection at 254 nm. In
addition to AG (retention time T 8-1 min)
N-acetylAG (T 11.0 min), N-formylAG (T
9-2 min) andnitroG (T28-4 min) weredetected
and characterized by mass spectrometry
(Baker et al., 1981) and comparison with
authentic compounds. N-AcetylAG and
nitroG were obtained by published methods
(Aboul-Enein et al., 1975); the preparation
of N-formylAG is described below. Compo-
nerAts were quantified by peak area with
reference to the responses to known quantities
of the authentic compounds.
Synthesis of N-formylAG.-A solution of
AG (232 mg; 1 mmol) in formic acid (1 ml)
was stored for 30 min at room temperature,
>,NHCOCH3
Et
O 0
N-Acetylaminoglutethimide
NHCHO
Et
O N 0
H
N-Formylaminoglutethimide
concentrated to dryness, and the residue was
crystallized from water-2-propanol, (9:1) to
yield the N-formyl derivative as colourless
crystals (160 mg, 61°%) m.p. 138-140°C.
Calculated for C14H16;N203:C, 65-5; H, 5-9;
N, 11.8%. Found: C, 65-6; H, 6-2; N, 11.8%.
RESULTS
Acetylator phenotype for sulphadimidine
and AG
The volunteers divided equally into
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FIG. I. Percentages of the administeredl dose of oral aminoglutethimide (250 mg, AG) excreted
in the urine during 24 hi by eachi of 10 volunteers as the major metabolite N-acetylAG (a) andl
AG (b). The acetylator plhenotype for sulplha(limidine acetylation is shown (viz. slow vs rapid).
Horizontal (lotted lines represent mean for eaclh acetylator phenotype; vertical lines sshow s.e.
rapid and slow acetylators of sulpha-
dimidine. Their 6h urine samples con-
tained, respectively, 89-96% and 62-68%
of the excreted dose as N-acetylsulpha-
dimidine. After taking AG, each rapid
acetylator of sulphadimidine excreted
more (P=0 01) N-acetylAG (mean, 8 8%O
of the administered dose) in the 24h urine
than did each slow acetylator (mean
3.90o) (Fig. la). Four out of 5 of these
rapid acetylators excreted more un-
changed AG (mean, 28% of administered
dose) than did the slow acetylators (mean,
12%; Fig. lb) but the difference beween
the acetylator phenotypes fell short of
statistical significance (P= 0.074).
Acetylatorphenotype and excretion ofnitroG
and N-formylAG
The mean percentages ofthe dose ofAG
excreted as nitroG (Fig. 2a) were higher
(P= 0.014) for the slow acetylators of
sulphadimidine (0I10O%) than for the rapid
acetylators (0.047%o). Four out of 5 of
these slow acetylators excreted more
nitroG than did the rapid acetylators.
The mean percentages excreted as N-
formylAG were virtually identical for the
slow (0-475%o) and the rapid (0-465%)
acetylators of sulphadimidine, though the
range of values recorded (Fig. 2b) was
greater for the rapid acetylators.
DISCUSSION
The present study affords compelling
evidence that AG is polymorphically
acetylated in humans. The results amplify
and confirm preliminary evidence for
polymorphic acetylation, based on plasmaPOLYMORPHIC ACETYLATION OF AMINOGLUTETHIMIDE
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FiG. 2.-Percentages of the administered dose of oral AG excreted as the minor
metabolites nitroG (a) and N-formylAG (b). Details as for Fig. 1.
levels of AG and its N-acetyl derivative
in these subjects. Thus Coombes et al.
(1980) found that levels ofN-acetylAG at
0O5, 2 and 8 h were significantly higher in
the 5 rapid acetylators (means of 1 06, 1 22
and 1 05 Kg/ml respectively) than in the 4
slow acetylators who were evaluated
(means of 0O50, 0 61 and 0-37 ,ug/ml
respectively). However, the levels ofAG in
the rapid acetylators (0.96, 0-60 and
0*85 jig/ml) and in the slow acetylators
(1.14, 1*10 and 0 07 xg/ml) did not differ
significantly. The present studies on the
urinary levels were not performed concur-
rently with the plasma determinations
because, in the HPLC analysis, it was
necessary to replace the linear tripartite
gradient between 20-50% aqueous meth-
anol used for the plasma measurements
with the present isocratic system. The
urinary levels of AG also showed some
24
overlap between the rapid and the slow
acetylator phenotypes, implying that the
bimodal distribution is less marked for the
acetylation ofAG than ofsulphadimidine.
The bimodal distribution in the output
of the minor metabolite nitroG deserves
comment. Formation of nitro derivatives
from their amino precursors is an unusual
metabolic transformation which probably
proceeds via an intermediate hydroxyl-
amino derivative. Thus both types of
compound have been isolated after micro-
somal metabolism of 4,4'-diaminodi-
phenylsulphone (Tyler et al., 1973;
Tabarelli & Uehleke, 1971) but it is
possible that the second step (hydroxyl-
amino---nitro) takes place non-enzymat-
ically, both in the cited example andin the
present case. Although polymorphism of
drug oxidation in man has also been
observed (Eichelbaum, 1981) it is unneces-
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sary to invoke it in order to explain the
distribution in nitroG levels. Thus the
rapid acetylators could excrete less nitroG
simply because the pool of AG available
for alternative pathways is depleted in
these subjects. Therefore bimodal distribu-
tion in nitroG execretion is probably a
reflection of acetylator phenotype.
The absence ofa bimodal distribution in
the excretion of N-formylAG requires
explanation, since on the foregoing argu-
ment this component should also be
depleted in the urine of rapid acetylators.
Formylation is also an infrequently ob-
served metabolic transformation, and
Stillwell etal. (1978) have cautioned that it
can occurartifactually byreaction between
basic -NH functions and phosgene gener-
ated from chloroform (and implicitly from
dichloromethane). However, this origin for
N-formylAG was discounted, since dich-
loromethane extracts of urine containing
known amounts of AG (used to construct
standard curves) contained none ofthe N-
formyl derivative as evidenced by HPLC
analysis. Formylation is mediated by the
enzyme kynurenine formamidase (aryl-
formyl-amine amino-hydrolase EC 3.5.1.9)
which promotes transfer ofa formyl group
from N-formyl-L-kynurenine to the amino
group of the substrate (Santii & Hopsu-
Havu, 1968). Should rapid acetylators of
AG also prove to be rapid formylators,
then the tendency for N-formylation to be
reduced in rapid acetylators (cf. nitroG)
would be counteracted by more rapid
formylation of the smaller pool of AG,
resulting in no net reduction of N-
formylation in therapid, as compared with
the slow acetylators.
As a result ofthe present demonstration
that AG is polymorphically acetylated,
patients are now routinely typed for
acetylator status (using sulphadimidine)
before starting AG therapy. Moreover,
since patients are treated chronically, i.e.
they are given daily doses of 1 g, as
opposed to the single 250 mg dose given to
the volunteers, plasma levels will be
monitored during therapy to see whether
these differ between the acetylator pheno-
types, despite the evidence that they do
not vary significantly after a single dose.
These proposed studies should enable a
retrospective assessment of any influence
of acetylator phenotype upon the magni-
tude and duration of response, as well as
on the nature and duration of side effects,
and may guide the selection ofpatients for
AG therapy, as well as the design of
analogues with improved therapeutic
benefit.
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